Playing the long game: will the ongoing evolution of the psoriasis market play out in atopic dermatitis?

With several advanced therapy options now available to treat moderate-severe atopic dermatitis - and more on the horizon - how is the treatment landscape changing? Can we use evolutions in psoriasis treatment as a proxy, and can we draw any parallels between physicians’ therapeutic goals?

Ipsos | Playing the long game In a follow-up edition to our 2019 point of view The Biologic Blueprint, we use Ipsos’ syndicated Atopic Dermatitis and Psoriasis Therapy Monitor data to compare developments across the two indications now additional advanced therapy options are available, and how physicians’ treatment goals and expectations are evolving in tandem.

Download the white paper

The author(s)

More insights about Health

Related news

  • KEYS: Our World in Motion
    E mobility Webinar

    [Webinar] KEYS: Our World in Motion

    At our next KEYS webinar, we’ll be launching the inaugural Ipsos Mobility Report.
  • [Webinar] Real evidence from real experiences: Patient Centric Evidence
    Healthcare Webinar

    [Webinar] Real evidence from real experiences: Patient Centric Evidence

    Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
  • Battle For Attention - KEYS Webinar from Ipsos
    Communications Events replay

    [Webinar] KEYS: Battle For Attention

    In today’s hyper-fragmented landscape, communicating using short-form content and social media platforms is an essential part of our toolkit. But are they better suited to short-term engagement rather than long-term brand building? And what does genuinely innovative and creative advertising look like these days?